ESR1 and breast cancer: Unfortunately, the proportion of LABC patients with HR+/HER2− breast cancer achieving pathologic complete response (pCR) after neoadjuvant chemotherapy is low, especially in patients with estrogen receptor-positive (ER+) or progesterone receptor-positive (PR+) tumors who are less sensitive to chemotherapy.